Antibacterial Therapy for Resistant Gram-Negative Infections
Meiji Seika Pharma Co. Ltd. focuses on antibacterial therapy for serious infections caused by carbapenem-resistant Enterobacterales, with research centered on treatment options for difficult-to-manage bacterial disease.
- Complicated urinary tract infection (cUTI)
- Acute uncomplicated pyelonephritis (AP)
- Carbapenem-resistant Enterobacterales (CRE)
The sponsor’s research activity includes clinical evaluation of combination antibacterial approaches in adult patients with resistant infections affecting the urinary tract and related systemic bacterial disease.
Hospital-Acquired and Ventilator-Associated Pneumonia
Another area of interest is hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, reflecting attention to severe lower respiratory tract infections in hospitalized adults.
- Hospital-acquired bacterial pneumonia (HABP)
- Ventilator-associated bacterial pneumonia (VABP)
These studies align with treatment needs in intensive care and inpatient settings where resistant pathogens and limited therapeutic options are major clinical concerns.
Complicated Intra-Abdominal Infection
The sponsor also supports research in complicated intra-abdominal infection, a major bacterial infection category requiring broad-spectrum treatment coverage and careful clinical management.
- Complicated intra-abdominal infection (cIAI)
- Adult infectious disease treatment
This area extends the sponsor’s antibacterial portfolio into severe abdominal infections associated with significant clinical complexity and resistant organisms.
Intravenous Anti-Infective Treatment Development
Meiji Seika Pharma Co. Ltd. is engaged in intravenous anti-infective research involving cefepime/nacubactam and aztreonam/nacubactam, with interest in treatment options for adults across multiple serious bacterial infections.
- Cefepime/nacubactam
- Aztreonam/nacubactam
- Imipenem/cilastatin
The clinical focus includes efficacy and safety assessment in infection settings where resistant pathogens complicate standard care.
